Cargando…

Effectiveness of fluvoxamine at preventing COVID-19 infection from turning severe

Detalles Bibliográficos
Autor principal:	Boretti, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. and ECNP. 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744705/ https://www.ncbi.nlm.nih.gov/pubmed/36640691 http://dx.doi.org/10.1016/j.euroneuro.2022.12.001

Ejemplares similares

Fluvoxamine for the treatment of COVID-19
por: Dodds, Michael G, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Boulware, David R, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Kim, Hyun, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Marzolini, Catia, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19 – Author's reply
por: Reis, Gilmar, et al.
Publicado: (2022)

Correspondence on Fluvoxamine Treatment of Patients with Symptomatic COVID-19
por: Sookaromdee, Pathum, et al.
Publicado: (2022)

Reply: Correspondence on Fluvoxamine Treatment of Patients with Symptomatic COVID-19
por: Seo, Hyeonji, et al.
Publicado: (2022)

Why we should not recommend or offer fluvoxamine to COVID-19 patients?
por: Trkulja, Vladimir
Publicado: (2022)

On the choice of Molnupiravir and Paxlovid as the only antivirals permitted for COVID-19 infection in Australia
por: Boretti, Alberto
Publicado: (2023)

Fluvoxamine and long COVID-19; a new role for sigma-1 receptor (S1R) agonists
por: Khani, Elnaz, et al.
Publicado: (2022)

Fluvoxamine, melatonin and COVID-19
por: Anderson, George M.
Publicado: (2021)

Comments to “Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists” by Khani and Entezari-Maleki
por: Hashimoto, Yaeko, et al.
Publicado: (2022)

Fluvoxamine for symptomatic outpatients with COVID-19
por: Wu, Peter E., et al.
Publicado: (2022)

Fluvoxamine
por: DeVane, C Lindsay
Publicado: (2005)

Severe Acute Cor Pulmonale in Patients with COVID-19 Acute Respiratory Distress Syndrome: Caution with Left Turn
por: Evrard, Bruno, et al.
Publicado: (2022)

Old drug fluvoxamine, new hope for COVID-19
por: Hashimoto, Yaeko, et al.
Publicado: (2021)

Overview of the potential use of fluvoxamine for COVID-19 and long COVID
por: Hashimoto, Kenji
Publicado: (2023)

Turning a surgical unit into a COVID-19 facility: Governance counts
por: Sfez, Michel, et al.
Publicado: (2020)

Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-analysis
por: Lee, Todd C., et al.
Publicado: (2022)

How nicotine can inhibit cytokine storm in the lungs and prevent or lessen the severity of COVID-19 infection?
por: Kloc, Malgorzata, et al.
Publicado: (2020)

Fluvoxamine for outpatients with COVID-19: where do we stand?
por: Berwanger, Otavio
Publicado: (2022)

Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19
por: Mahdi, Mohamed, et al.
Publicado: (2022)

Mechanisms of action of fluvoxamine for COVID-19: a historical review
por: Hashimoto, Yaeko, et al.
Publicado: (2022)

Legitimacy in international law of Australian border closure to own citizens
por: Boretti, A.
Publicado: (2022)

Moving towards a precision approach for prevention of severe COVID-19
por: Branch-Elliman, Westyn, et al.
Publicado: (2023)

COVID-19 and improved prevention of hospital-acquired infection
por: Hu, Ling-Qun, et al.
Publicado: (2020)

Fluvoxamine in the treatment of anxiety disorders
por: Irons, Jane
Publicado: (2005)

Decoupling of omicron variant infections and severe COVID-19
por: Madhi, Shabir A, et al.
Publicado: (2022)

Heme oxygenase agonists—fluvoxamine, melatonin—are efficacious therapy for Covid-19
por: Hooper, Philip L.
Publicado: (2021)

Repurposing fluvoxamine, and other psychiatric medications, for COVID‐19 and other conditions
por: Lenze, Eric J., et al.
Publicado: (2022)

Epidermoid Cyst Turned Out to be a Common Viral Infection in an Uncommon Site!
por: Seth, Joly, et al.
Publicado: (2016)

Pharmacotherapy for COVID-19 infection in the countries of the Cooperation Council for the Arab States
por: Boretti, Alberto
Publicado: (2021)

Is prostate infarction and acute urinary retention a possible complication of severe COVID-19 infection?
por: Duarte, Sergio A.C., et al.
Publicado: (2020)

COVID-19: an opportunity to improve infection prevention and control in LMICs
por: Maina, Michuki, et al.
Publicado: (2020)

A recruiting failure turned success
por: Hure, Alexis J, et al.
Publicado: (2008)

Proteinuria in Covid-19 pregnant women: Preeclampsia or severe infection?
por: Dap, Matthieu, et al.
Publicado: (2020)

Moving towards a precision approach for prevention of severe COVID-19 – Authors' reply
por: Agrawal, Utkarsh, et al.
Publicado: (2023)

Zinc augments the antiviral potential of HCQ/CQ and ivermectin to reduce the risks of more serious outcomes from COVID-19 infection
por: Boretti, Alberto
Publicado: (2022)

“No turning back” Psycho‐oncology in the time of COVID‐19: Insights from a survey of UK professionals
por: Archer, Stephanie, et al.
Publicado: (2020)

Toxic Effects from Ivermectin Use Associated with Prevention and Treatment of Covid-19
por: Temple, Courtney, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t1145iucaesn9744dq79ecpceh